Novartis AG (NOVN) - Total Liabilities

Latest as of December 2025: CHF68.97 Billion CHF

Based on the latest financial reports, Novartis AG (NOVN) has total liabilities worth CHF68.97 Billion CHF as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Novartis AG - Total Liabilities Trend (1998–2025)

This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company	Country	Total Liabilities
Wells Fargo & Company NYSE:WFC	USA	$1.97 Trillion
Philip Morris International Inc NYSE:PM	USA	$77.21 Billion
Westpac Banking Corporation AU:WBCPI	Australia	AU$1.03 Trillion
China Construction Bank Corporation F:C6T	Germany	€41.95 Trillion
Royal Bank of Canada NYSE:RY	USA	$2.21 Trillion
Goldman Sachs Group Inc NYSE:GS	USA	$1.68 Trillion
Intel Corporation NASDAQ:INTC	USA	$85.07 Billion

Liability Composition Analysis (1998–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.12	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.42	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (1998–2025)

The table below shows the annual total liabilities of Novartis AG from 1998 to 2025.

Year	Total Liabilities	Change
2025-12-31	CHF68.97 Billion	+18.68%
2024-12-31	CHF58.12 Billion	+9.26%
2023-12-31	CHF53.20 Billion	-8.33%
2022-12-31	CHF58.03 Billion	-9.29%
2021-12-31	CHF63.97 Billion	-10.04%
2020-12-31	CHF71.11 Billion	+13.20%
2019-12-31	CHF62.82 Billion	-6.06%
2018-12-31	CHF66.87 Billion	+13.63%
2017-12-31	CHF58.85 Billion	+6.55%
2016-12-31	CHF55.23 Billion	+1.47%
2015-12-31	CHF54.43 Billion	-0.20%
2014-12-31	CHF54.54 Billion	+5.33%
2013-12-31	CHF51.78 Billion	-5.73%
2012-12-31	CHF54.93 Billion	+6.54%
2011-12-31	CHF51.56 Billion	-3.72%
2010-12-31	CHF53.55 Billion	+40.76%
2009-12-31	CHF38.04 Billion	+36.54%
2008-12-31	CHF27.86 Billion	+6.93%
2007-12-31	CHF26.06 Billion	-2.46%
2006-12-31	CHF26.71 Billion	+8.73%
2005-12-31	CHF24.57 Billion	+16.03%
2004-12-31	CHF21.17 Billion	+12.63%
2003-12-31	CHF18.80 Billion	+12.63%
2002-12-31	CHF16.69 Billion	+13.18%
2001-12-31	CHF14.75 Billion	+11.97%
2000-12-31	CHF13.17 Billion	-25.33%
1999-12-31	CHF17.64 Billion	-1.49%
1998-12-31	CHF17.90 Billion	--

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General

Market Cap

$285.29 Billion

CHF225.66 Billion CHF

Market Cap Rank

#69 Global

#2 in Switzerland

Share Price

CHF118.26

Change (1 day)

+0.72%

52-Week Range

CHF89.34 - CHF130.50

All Time High

CHF130.50